Medical Advocates
Nevirapine (Viramune)
 
Journal Citations:
Therapeutic Strategies
 
Drug Monitoring                         Stopping NVP Therapies             
Tolerance Induction                   Adherence and Dosing 
Cryptococcal Prophylaxis           IDUs   
Lipodystrophy Prevention          HIV/TB Coinfection
HIV Pre-exposure Prophylaxis   HIV/Malaria Coinfection
Coronary Risk                             HIV/HCV Coinfection
CNS Benefits
 Undetectable Viral Load
 Switching Therapies
Simplification Therapy
 Salvage Therapy   
NVP Main Page  Journal Main Page Main New/Newsworthy  Home Page
Last Update:  April 13, 2017
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Drug Monitoring
 
 
Efavirenz and Nevirapine in HIV-1 Infection : Is There a Role for Clinical
Pharmacokinetic Monitoring?
 Dahri K, Ensom MH. 
Clin Pharmacokinet. 2007;46(2):109-32.
 Abstract

Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia.
 Martorell M, Lopez RM, Ribera E
Enferm Infecc Microbiol Clin. 2005 Jun;23(6):349-5
 Abstract
Tolerance Induction
           
  Long-term safety and efficacy of nevirapine tolerance induction.
 Messaad D, Reynes J, Fabre J, et al.
Clin Exp Allergy. 2002 May;32(5):733-735.
 Abstract		  
NVP-Based HAART and Fluconazole Cryptococcal
Prophylaxis
  FULL-TEXT PDF ARTICLE
 Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients
receiving fluconazole for cryptococcal prophylaxis: a case-control study
 Manosuthi W, Chumpathat N, Chaovavanich A, Sungkanuparph S 
BMC Infectious Diseases 2005, 5:67
Paper		  
Lipodystrophy Prevention
           
  Switching to nevirapine decreases insulin levels but does not improve subcutaneous a
dipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy.
Domingo P, Matias-Guiu X, Pujol RM, et al.
J Infect Dis 2001 Nov 1;184(9):1197-201
 Abstract 		 
Coronary Risk
           
  A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus
in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized
controlled study.
 Fisac C, Virgili N, Ferrer E, et al  J
Clin Endocrinol Metab. 2003 Nov;88(11):5186-92
 Abstract
Central Nervous System Benefits
           
  Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous
system in HIV-1-infected patients.
 von Giesen HJ, Koller H, Theisen A, Arendt G.
 J Acquir Immune Defic Syndr 2002 Apr 1;29(4):363-7
 Abstract		  
Undetectable Viral Load
 		  
  Long-Term Efficacy and Safety of Protease Inhibitor Switching to Nevirapine in HIV
-Infected Patients with Undetectable Virus Load.
 Gil P, de Gorgolas M, Estrada V 
Clin Infect Dis. 2004 Oct 1;39(7):1024-9
 Abstract		  
Simplification Therapy
 
  Once-a-day (QD) vs. Twice-daily (BID) Nevirapine as Simplification in PI-Treated Patients
after 2 mos. of BID Induction.
Maserati R, Brandolini M, Cattelan A,
Curr HIV Res. 2011 Mar 29
 Abstract

Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with
nevirapine, efavirenz or abacavir.
 de Echaguen AO, Arnedo M, Xercavins M, et al
AIDS. 2005 Sep 2;19(13):1385-1391.
Abstract
Salvage Therapy
           
  Nelfinavir plus nevirapine plus two nrtis as salvage therapy for hiv-infected patients receiving
antiretroviral treatment.
Perez-Molina JA, Perez Nr R, et al  
HIV Clin Trials 2001 Jan-Feb;2(1):1-5
Abstract
 
Efficacy of a nelfinavir- and nevirapine-containing salvage regimen.
Sullivan AK, Nelson MR, Shaw A, et al
HIV Clin Trials 2000 Jul-Aug;1(1):7-12
 Abstract
 
Stopping NVP-Based Therapy
           
 
Discontinuation rate of Nevirapine-based HAART.
Górgolas M, Hidalgo C, Williams F, Fernandez Guerrero ML.
AIDS Res Hum Retroviruses. 2011 May 11
 Abstract

Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic
resistance after treatment interruption.
 Darwich L, Esteve A, Ruiz L, et al
Antivir Ther. 2008;13(7):945-51.
 Abstract
 
Reasons for discontinuation of nevirapine-containing HAART: results from an unselected
population of a large clinical cohort.
 Maggiolo F, Arici C, Airoldi M,  et al 
J Antimicrob Chemother. 2007 Jan 25;
 Abstract

Clinical implications of stopping nevirapine-based antiretroviral therapy: relative
pharmacokinetics and avoidance of drug resistance.
 Mackie N, Fidler S, Tamm N, et al 
HIV Med. 2004 May;5(3):180-184
 Abstract

Adherence and Dosing
 
  Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized
controlled study.
 Parienti JJ, Massari V, Reliquet V, et  a
AIDS. 2007 Oct;21(16):2217-2222.
 Abstract
HIV Pre-exposure Prophylaxis
 
  Evaluation of Polycaprolactone Matrices for Sustained Vaginal Delivery of Nevirapine in the Prevention of Heterosexual HIV Transmission.
Dang N, Sivakumaran H, Harrich D, et al
 J Pharm Sci. 2014 May 27.
 Abstract

A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission
in uninfected subjects at high risk.
 Jackson JB, Barnett S, Piwowar-Manning E, et al.
AIDS 2003 Mar 7;17(4):547-53
 Abstract
HIV/HCV Coinfection
           
  FULL-TEXT ARTICLE
Proteomic Analysis of Serum and Urine of HIV-Monoinfected and HIV/HCV-Coinfected Patients Undergoing Long Term Treatment with Nevirapine.
 Wongtrakul J, Thongtan T, Roytrakul S, et al 
Dis Markers. 2014;2014:315824.
Paper

Long-term safety and tolerability of nevirapine and efavirenz-containing regimens in HIV/HCV-coinfected patients.
 Mauelshagen A, Horst H, Stellbrink H, Hoffmann C.
 J Int AIDS Soc. 2012 Nov 11;15(6):18416.
Abstract

HIV/TB Coinfection
           
 
FULL-TEXT ARTICLE
Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.
 Bhatt NB, Baudin E, Meggi B, da Silva C,  et al
J Antimicrob Chemother. 2014 Sep 18.
Paper

Impact of lopinavir/ritonavir or nevirapine on bedaquiline exposures: potential implications for patients with TB/HIV co-infection
Svensson EM, Dooley KE, Karlsson MO.
Antimicrob Agents Chemother. 2014 Aug 11
 Abstract

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
 Jiang HY, Zhang MN, Chen HJ, et al
Int J Infect Dis. 2014 Jun 6.
Abstract

Pharmacokinetics of Rifampicin and Isoniazid in Tuberculosis-HIV Co-infected Patients Receiving Nevirapine or Efavirenz Based Antiretroviral Treatment (ANRS 12214 study).
 Bhatt NB, Barau C, Amin A, et al
Antimicrob Agents Chemother. 2014 Mar 24
 Abstract

The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals
Decloedt EH, Mwansa-Kambafwile J, van der Walt JS,  et al
 Int J Tuberc Lung Dis. 2013 Mar;17(3):333-5.
Abstract

FULL-TEXT PDF ARTICLE
 The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in
HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment.
 Sinha S, Dhooria S, Kumar S,  et al
 AIDS Res Ther. 2011 Nov 2;8(1):41
Paper

Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in HIV-Associated Tuberculosis:
A Randomized Clinical Trial.
 Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G,  et al
Clin Infect Dis. 2011 Oct;53(7):716-24.
 Abstract

Treatment outcomes of patients co-infected with HIV and tuberculosis who received a
nevirapine-based antiretroviral regimen: a four-year prospective study.
 Manosuthi W, Tantanathip P, Chimsuntorn S, et al
Int J Infect Dis. 2010 Sep 27.
Abstract

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine
levels when co-administered with rifampicin in HIV/TB co-infected Thai adults.
 Uttayamakul S, Likanonsakul S, Manosuthi W,  et al 
AIDS Res Ther. 2010 Mar 26;7(1):8
 Abstract

Outcomes and safety of concomitant nevirapine and rifampicin treatment under
programme conditions in Malawi.
Moses M, Zachariah R, Tayler-Smith K, Misinde D, et al
Int J Tuberc Lung Dis. 2010 Feb;14(2):197-202.
 Abstract

Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients
coinfected with HIV-1 and tuberculosis.
 Matteelli A, Saleri N, Villani P, et al 
J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):64-9
 Abstract

Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-
based antiretroviral therapy in HIV-infected patients with tuberculosis.
Manosuthi W, Ruxrungtham K, Likanonsakul S, et al
 Clin Infect Dis. 2007 Jan 1;44(1):141-4.
 Abstract

Increasing Nevirapine Dose Can Overcome Reduced Bioavailability Due to Rifampicin
Coadministration.
 Ramachandran G, Hemanthkumar AK, Rajasekaran S,  
Acquir Immune Defic Syndr. 2006 Apr 24;
Abstract

HIV/Malaria Coinfection
 
 
Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in
HIV-Infected Nigerian Adults.
Fehintola FA, Scarsi KK, Ma Q,  et al
AIDS Res Treat. 2012;2012:703604.
Abstract

FULL-TEXT ARTICL
 The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based
Antiretroviral Treatment.
Skinner-Adams TS , Butterworth AS , Porter KA , et al.
PLoS ONE 7(4): e34399.
Paper

FULL-TEXT ARTICLE
 Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition
in HIV-Infected Nigerian Adults,
 Fatai A. Fehintola, Kimberly K. Scarsi, et al
AIDS Research and Treatment Vol 2012 , Art ID 703604
 Paper

Malaria therapy in HIV: drug interactions between nevirapine and quinine.
Uriel A, Lewthwaite P
 Int J STD AIDS. 2011 Dec;22(12):768.
 Abstract

Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers.
 Soyinka JO, Onyeji CO, Omoruyi SI, et al
J Pharm Pharmacol. 2009 Apr;61(4):439-43.
 Abstract

NVP Main Page Journal Main Page Main New/Newsworthy  Home Page

Nevirapine Journal Data
Therapeutic Strategies